Blood cancers

Disappointment as eltrombopag does more harm than good in AML trial

Disappointing negative trial results have dashed hopes for the thrombopopoietin receptor agonist eltrombopag as adjuvant therapy in patients with acute myeloid leukaemia. Combining eltrombopag with standard induction therapy of daunorubicin and cytarabine appeared to do more harm than good in AML patients, according to results from a phase 2 randomised double blind trial conducted in ...

Already a member?

Login to keep reading.

© 2021 the limbic